Curazene.com isn't a biotech startup—it's a $4.2M revenue company selling its own name. In a market where domain names sell for millions, this 27-employee entity exists in a fascinating twilight zone between brand asset and operating business.

"They're not building a biotech product—they're selling the possibility of one."

The tech stack tells another story. With jQuery, Ant Design, and Vite powering a domain listing page, this isn't a biotech platform—it's a marketplace dressed in medical colors. The $4.2M revenue suggests either high-margin domain sales or a creative accounting of 'potential' value. For founders and investors, this represents a fascinating case study in asset valuation versus operational reality.

• Premium domain with biotech branding positioned for acquisition
• Revenue-generating entity with unclear operational focus
• Zero organic traffic indicates asset holding, not active development
• 27-person team suggests substantial overhead for a domain seller
• High-tech stack for what appears to be a simple listing page